Gynecologic Oncology Group (GOG) Trials – Chart

A Phase III Randomized Trial of Pulse Actinomcyin-D versus Multi-day Methotrexate for the Management of Low Risk Gestational Trophoblastic Neoplasia

Title Protocol IDs Phase

Ovarian Cancer (non-sarcoma)

Bevacizumab With or Without Fosbretabulin Tromethamine (CA4P)in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer GOG 0186I Phase II
A Randomized Phase IIB Evaluation of Pazopanib versus Weekly Paclitaxel plus Pazopanib versus Weekly Paclitaxel in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma GOG
0186J
Phase
IIb
A Randomized Phase II Study of Cabozantinib (NSC #761968) Versus Weekly Paclitaxel (NSC #673089) in The Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer GOG
0186K
Phase
II
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT-2103(IND# 70177) Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy GOG
0212
Phase
III
A randomized phase III trial comparing secondary debulking surgery versus no surgery and comparing chemotherapy with bevacizumab versus chemotherapy without bevacizumab among those who fail first-line chemotherapy GOG
0213
Phase III
GOG
0225
Pre-vention
GOG
0241
Phase
III
Phase III Randomized Study of Two Different Dose Schedules of Paclitaxel in Combination with Carboplatin with versus without Concurrent and Consolidation Bevacizumab in Patients With Stage III-IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (GOG-0262). GOG
0262
Phase
III
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer GOG
0268
Phase II
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer GOG 0273 Pilot
GOG
3001
Phase
III
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer GOG
3003
Phase
II
GOG
9923
Phase
I
GOG
9924
Phase
I
A Phase I Study Of VTX-2337 (IND #78,416) In Combination With Pegylated Liposomal Doxorubicin (PLD;NSC# 712227) In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Cancer GOG
9925
Phase
I
Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer GOG 9927 Phase I
GOG
9928
Phase
I

Uterine (Endometrial) Cancer

GOG
0238
Phase
II
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma GOG 0250 Phase III
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma GOG
0258
Phase
III
GOG
0261
Phase
III

Cervical Cancer

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer GOG 0076HH Phase II
Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery GOG 0263 Phase III
A Phase II Evaluation of ADXS11-001 (NSC 752718,BB-IND#13,712) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix GOG
0265
Phase
II
A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY FOLLOWING CHEMORADIATION AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE (ANZGOG 0902/GOG-0274) GOG
0274
Phase
III
Evaluation Of Physical Function And Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) For Stage IA1 (LVSI+) and IA2-IB1 (<=2cm) Cervical Cancer GOG
0278
Quality
of
Life
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiotherapy With Versus Without Adjuvant Chemotherapy in Patients With High-Risk Early-Stage Cervical Carcinoma After Radical Hysterectomy GOG 0724 Phase III
Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer GOG 9926 Phase I
GOG
9929
Phase
I

Other: Ovarian Sarcoma

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer GOG 0261 Phase III

Other: Trophoblastic

A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia GOG
0275
Phase
III

Other: Uterine Sarcoma

A Phase III Randomized Trial Of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed By Doxorubicin (NSC# 123127) V. Observation For Uterus-Limited, High Grade Uterine Leiomyosarcoma GOG
0277
Phase
III

 

 

Spotlight

This special section in Self Magazine features a GYN surgeon and 34-year-old (at the time of diagnosis) patient.

Awareness

This year’s National Race to End Women’s Cancer aims to spread the word that all women should Love Your Ladyparts! Check out site’s new features and join the MOVEMENT.

Research

The Foundation’s research award winners will be notified in January. Thank you to all who sent in their applications.

Education

The next Ovarian Cancer Survivors Course will be Saturday, Nov. 1, 2014 in D.C. For more information on educational events and courses, click here.